Cytokinetics/$CYTK

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Cytokinetics

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Ticker

$CYTK
Primary listing

Industry

Biotechnology

Employees

498

ISIN

US23282W6057

Cytokinetics Metrics

BasicAdvanced
$4.4B
-
-$5.30
0.81
-

What the Analysts think about Cytokinetics

Analyst ratings (Buy, Hold, Sell) for Cytokinetics stock.

Bulls say / Bears say

Cytokinetics' lead drug candidate, aficamten, is in Phase III trials for hypertrophic cardiomyopathy, addressing a significant unmet medical need and potentially leading to substantial market adoption upon approval. (Investing.com)
Analysts have set an average price target of $70.92 for CYTK, indicating a potential upside of over 100% from its current trading price. (MarketBeat)
The company has established strategic partnerships, such as with Ji Xing Pharmaceuticals, to expand its global footprint and enhance its pipeline's potential reach. (DirectorsTalkInterviews)
Cytokinetics reported a net loss of $589.53 million in 2024, reflecting the high costs associated with ongoing research and development. (StockAnalysis)
The company's stock is currently trading below both its 50-day and 200-day moving averages, indicating potential bearish momentum. (TipRanks)
As a late-stage biopharmaceutical company, Cytokinetics faces inherent risks related to clinical trial outcomes and regulatory approvals, which could impact its financial stability and stock performance. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.

Cytokinetics Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Cytokinetics Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CYTK

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs